{
    "nct_id": "NCT05081609",
    "official_title": "IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
    "inclusion_criteria": "* At least 18 years of age, or country defined local legal age\n* Demonstrated adequate organ function at screening\n* Life expectancy >12 weeks as determined by the Investigator\n* Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception\n* Participants must have histologically confirmed locally advanced, recurrent, or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the neoadjuvant cohorts\n* Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a washout of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts\n* Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to ≤Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement\n* Part 3: Neoadjuvant cohorts: participants must have completely resectable disease\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic central nervous system metastases and/or carcinomatous meningitis\n* Active autoimmune diseases, regardless of need for immunosuppressive treatment, with the exception of participants well controlled on physiologic endocrine replacement\n* Any uncontrolled bacterial, fungal, viral, or other infection\n* Significant cardiac disease\n* A marked clinically significant baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 ms) [CTCAE Grade 1]) using Fridericia's QT correction formula\n* Positive for human immunodeficiency virus (HIV) or has known active hepatitis B or C infection\n* Known hypersensitivity to any study treatment(s) used in the specific study part/cohort\n* Participants who have been previously treated with IL-2 or IL-2 variants (all participants)\n* Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation).\n* Vaccination with live, attenuated vaccines within 4 weeks of C1D1\n* Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of C1D1\n* Part 3: Other active malignancies within the last 2 years\n* Women who are breastfeeding or have a positive serum pregnancy test during screening",
    "miscellaneous_criteria": "Key"
}